UK Companies House feature
ICON CLINICAL RESEARCH (U.K.) NO. 2 LIMITED
Profile
- Company number
- 08630390
- Status
- Active
- Incorporation
- 2013-07-30
- Last accounts made up
- 2024-12-31
- Account category
- FULL
- Primary SIC
- 86900
- Hubs
- UK Healthcare
Accounts
Pending extraction
No iXBRL extracted yet for this company.
Audit & accounting basis
From AI-extracted PDF accounts
- Accounting basis
- FRS 101 Reduced Disclosure Framework
- Reporting scope
- Standalone (parent only)
- Auditor
- KPMG
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“The financial statements have been prepared on the going concern basis. The ICON plc group, of which the Company is a member, also continues to adopt the going concern basis in preparing its financial statements.”
Significant events
- “On 31 May 2025, ICON Clinical Research (U.K.) No. 3 Limited transferred the entire issued share capital of the Company, comprising 2 ordinary shares, to ICON Clinical Research (U.K.) Limited, which is now the sole shareholder of the Company.”
- “On 31 May 2025, the Company entered into a business transfer agreement to sell the business and undertakings, including all employees, assets and liabilities of the Company to Pharm Research Associates (UK) Limited in exchange for issuance of 9,081 ordinary shares in Pharm Research Associates (UK) Limited.”
- “On 2 June 2025, Pharm Research Associates (UK) Limited changed its name to ICON Clinical (UK) Limited.”
- “On 27 June 2025, the Company transferred its 9,081 ordinary shares in ICON Clinical (UK) Limited to ICON Clinical Research (U.K.) Limited for £4,447,200 to be left outstanding as an intercompany loan.”
- “On 2 June 2025, the Company's registered address changed to 3rd Floor, North & South Wings, 100 Longwater Avenue, Green Park, Reading, Berkshire, RG2 6GP, United Kingdom.”
Auditor / going-concern / subsidiary information is extracted from the PDF version of the latest annual accounts and is not tagged in iXBRL. About these numbers
People
3 active · 9 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| FOX, Erina, Ms. | Secretary | 2017-07-27 | — | — |
| HOLMES, Simon | Director | 2017-07-27 | Dec 1966 | British |
| SHEEHAN, Alan | Director | 2017-07-27 | Sep 1978 | Irish |
Show 9 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| PAGE, Nigel Granville | Secretary | 2014-12-30 | 2017-07-27 |
| SPICOLA, Brigid | Secretary | 2013-07-30 | 2014-12-30 |
| ANDERSON, Neil David | Director | 2014-01-15 | 2014-12-30 |
| BERRYMAN, David Robert | Director | 2014-09-05 | 2014-12-30 |
| BLAZEI, Alan Steven | Director | 2014-12-30 | 2017-12-01 |
| FORD, Stephen Kelsey | Director | 2013-07-30 | 2014-01-15 |
| GLEESON, Michael | Director | 2017-07-27 | 2022-10-21 |
| KARIS, James Michael | Director | 2014-12-30 | 2017-07-27 |
| PAGE, Nigel Granville | Director | 2016-08-24 | 2018-06-08 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Icon Clinical Research (U.K.) Limited | Corporate entity | Shares 75–100%, Voting 75–100% | 2025-05-31 | Active |
| Icon Clinical Research (U.K.) No. 3 Limited | Corporate entity | Shares 75–100% | 2017-07-19 | Ceased 2025-05-31 |
| Mr Nigel Granville Page | Individual | Significant influence | 2016-04-06 | Ceased 2017-07-19 |
| Director James Karis | Individual | significant-influence-or-control-as-trust | 2016-04-06 | Ceased 2017-07-19 |
| Director Alan Blazei | Individual | Significant influence | 2016-04-06 | Ceased 2017-07-19 |
Filing timeline
Last 20 of 81 total filings
| Date | Type | Category | Description |
|---|---|---|---|
| 2026-04-21 | CS01 | confirmation-statement | confirmation statement with updates |
| 2026-01-30 | AUD | auditors | auditors resignation company |
| 2026-01-07 | AA | accounts | accounts with accounts type full |
| 2025-06-02 | PSC02 | persons-with-significant-control | notification of a person with significant control |
| 2025-06-02 | PSC07 | persons-with-significant-control | cessation of a person with significant control |
| 2025-06-02 | AD01 | address | change registered office address company with date old address new address |
| 2025-03-21 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2024-12-04 | AA | accounts | accounts with accounts type full |
| 2024-03-15 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2024-01-04 | AA | accounts | accounts with accounts type full |
| 2023-03-23 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2023-01-05 | AA | accounts | accounts with accounts type full |
| 2022-12-06 | TM01 | officers | termination director company with name termination date |
| 2022-03-31 | CS01 | confirmation-statement | confirmation statement with updates |
| 2022-03-31 | PSC05 | persons-with-significant-control | change to a person with significant control |
| 2021-12-31 | AA | accounts | accounts with accounts type full |
| 2021-10-05 | AD01 | address | change registered office address company with date old address new address |
| 2021-04-19 | RESOLUTIONS | resolution | resolution |
| 2021-03-18 | CS01 | confirmation-statement | confirmation statement with no updates |
| 2021-01-05 | AA | accounts | accounts with accounts type full |
Credit score
Altman Z″ — composite of working capital, retained earnings, EBIT, and leverage
Credit score requires extracted accounts data.
Activity Score
Filings velocity, capital events, officer churn, accounts trajectory
Activity Score not yet computed for this company.